1 Godwin AK,Testa JR,Hamilton TC.The biology of ovarian cancer development.Cancer,1993,71:530-536. 2 Ovarian cancer,five-year stage-specific relative survival rates(2004-2008).J Natl Cancer Inst,2011,103:1287. 3 Lisabeth EM,Falivelli G,Pasquale EB.Eph Receptor Signaling and Ephrins.Cold Spring Harb Perspect Biol,2013,5:a009159. 4 Yang X,Cheng L,Dai S,et al.Increased EphA/ephrinA expression in hippocampus of pilocarpine treated mouse.Epilepsy Research,2013,105:20-29. 5 Xi HQ,Wu XS,Wei B,et al.Eph receptors and ephrins as targets for cancer therapy.J Cell Mol Med,2012,16:2894-2909. 6 Mosch B,Reissenweber B,Neuber C,et al.Eph receptors and ephrin ligands:important players in angiogenesis and tumor angiogenesis.J Oncol,2010,2010:135285. 7 Pasquale EB.Eph receptors and ephrins in cancer:bidirectional signaling and beyond.Nat Rev Cancer,2010 ,10:165-180. 8 Cheng N,Brantley DM,Liu H,et al.Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.Mol Cancer Res,2002,1:2-11. 9 柳杨,段丽君,万素芳.卵巢癌组织中Wnt信号通路活性检测及肿瘤恶性生物学行为的评估.海南医学院学报,2015,21:724-727. 10 Martiny-Baron G,Holzer P,Billy E,et al.The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.Angiogenesis,2010,13:259-267. 11 Yao D,Dai C,Peng S.Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.Mol Cancer Res,2011,9:1608-1620. 12 Marchini S,Fruscio R,Clivio L,et al.Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.Eur J Cancer,2013,49:520-530. 13 Li RX,Chen ZH,Chen ZK.The role of EPH receptors in cancer-related epithelial-mesenchymal transition.Chin J Cancer,2014 ,33:231-240. 14 Huang J,Xiao D,Li G,et al.EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells.Oncogene,2014,33:2737-2747. 15 Yuki W,Koichi M.EphrinA1- EphA2 signal induces compaction and polarization of madin-darby Ccanine kidney cells by inactivating ezrin through negative regulation of RhoA.J Biol Chem,2011,286:44243-44253. 16 Walker DJ,Hess AR,Hendrix MJ,et al.Differential regulation of EphA2 in normal and malignant cels.Am J Pathol,2003,162:1037-1042. 17 徐敏,李洁华,徐丹,等.卵巢上皮性肿瘤中EphA2与临床病理及预后的关系.安徽医学,2010,31:1030-1032. 18 Lin YG,Han LY,Kamat AA,et al.EphA2 over expression is associated with angiogenesis in ovarian cancer.Cancer,2007,109:332 -340. 19 Wong YL,Dali AZ,Mohamed Rose I,et al.Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling.Asia Pac J Clin Oncol,2014,27:12182. 20 王海燕,彭李博,王建军,等.EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义.临床肿瘤学杂志,2014,19:996-999. 21 王玉楼,张静艳,温秋婷.EphA4在人上皮性卵巢癌中的表达及临床意义.肿瘤预防与治疗.2014,27:16-19. 22 陆玉霞,王建东,孙丽,等.EphA5蛋白在浆液性卵巢癌中的表达及临床意义.临床检验杂志,2015,33:279-281. 23 Wang G,Wen J,Wang H,et al.Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival.Int J Clin Exp Pathol,2014; 7 :313-321. 24 戴颖青,张洋,刘琦,等.卵巢浆液性腺癌中EphA2 和EphB2 的表达及意义.临床与实验病理学杂志,2013,29:502-505. 25 Alam SM,Fujimoto J,Jahan I,et al.Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.Br J Cancer,2008,98:845-851.
